This study investigates the impact of an 8-week ballet-based dance therapy on people with Parkinson's disease. It aims to assess the effect of ballet on motor and non-motor symptoms, such as balance, cognitive function, functional capacity, and quality of life. The study will provide insights into the potential of ballet therapy as an effective, non-pharmacological treatment for Parkinson's disease.
This clinical trial aims to evaluate the effects of an 8-week ballet-based dance therapy on individuals with Parkinson's disease. The intervention will target motor and non-motor symptoms, including functional capacity, balance, cognitive function, and quality of life. Participants will be randomly assigned to either the intervention group or a control group. The intervention group will engage in structured ballet classes, while the control group will receive standard care. Assessments will include measures of respiratory function, body composition, muscle strength, and balance, with evaluations conducted before and after the intervention. The goal is to assess the feasibility and effectiveness of ballet as a therapeutic approach to improve both physical and mental well-being in people with Parkinson's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
24
An 8-week ballet-based dance therapy program designed to improve balance, flexibility, peripheral muscle strength, cognitive functions, and overall functional capacity in Parkinson's disease patients. The therapy will be conducted twice a week, with each session lasting approximately 60 minutes. The exercises will be adapted to the participants' physical abilities and will focus on enhancing motor coordination, strength, and stability through ballet-inspired movements.
Participants in the control group will receive standard care for Parkinson's disease, including pharmacological management and routine clinical follow-up. Additionally, they will receive a one-time exercise counseling session and an informational brochure outlining general home-based exercises appropriate for individuals with Parkinson's disease. No supervised or structured exercise sessions will be conducted.
Functional Capacity
Functional capacity will be assessed using the Six-Minute Walk Test (6MWT) according to American Thoracic Society (ATS) guidelines. The total distance walked will be recorded.
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Forced Expiratory Volume in 1 Second (FEV₁)
FEV₁ will be assessed using spirometry and reported in liters (L). FEV1 will be measured according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Forced Vital Capacity (FVC)
FVC will be assessed using spirometry and reported in liters (L). FVC will be measured according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Tiffeneau Index (FEV₁/FVC Ratio)
The ratio of FEV₁ to FVC will be calculated using spirometry and reported as a percentage (%).
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Peak Expiratory Flow (PEF)
PEF will be assessed using spirometry and reported in liters per minute (L/min). PEF will be measured according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Forced Expiratory Flow 25-75% (FEF₂₅-₇₅%)
FEF₂₅-₇₅% will be assessed using spirometry and reported in liters per second (L/s). FEF₂₅-₇₅%will be measured according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Respiratory Muscle Strength
Respiratory muscle strength will be assessed by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) using a digital mouth pressure device, in accordance with established respiratory assessment guidelines.
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Balance
Balance performance will be assessed using the Biodex Balance System. Stability indices will be calculated to evaluate postural control and balance.
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Cognitive Function
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA is a 30-point scale ranging from 0 to 30, where higher scores indicate better cognitive performance.
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Peripheral Muscle Strength
Peripheral muscle strength will be assessed using a hand-held dynamometer for major lower extremity muscle groups.
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
Change in Quality of Life
Quality of life will be assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39). The total score ranges from 0 to 100, with higher scores indicating worse quality of life.
Time frame: At baseline and at week 9 (after 8 weeks of intervention)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.